Ultragenyx Pharmaceutical Shares Rise 5% After Divestiture

Key numbers

Deal value	$210M
Share of market cap	14.7%
Share of annual revenue	31.2%

Key highlights

• Divestiture of a Rare Pediatric Disease Priority Review Voucher for $210 million in cash
• Company will pay 20% of gross proceeds, totaling $42 million, to the NIH
• Voucher awarded following the August 19, 2026, FDA approval of GENGLYCOS
• Closing is subject to Hart-Scott-Rodino Antitrust Improvements Act clearance
• Transaction provides non-dilutive capital to support the rare disease pipeline

What Is Being Divested?

Ultragenyx Pharmaceutical Inc. entered into a definitive asset purchase agreement on October 6, 2026, to sell its Rare Pediatric Disease Priority Review Voucher to an undisclosed buyer. The FDA awarded this voucher on August 19, 2026, in conjunction with the approval of GENGLYCOS, also known as pariglasgene brecaparvovec-opnr, for adult and pediatric patients with glycogen storage disease type Ia. The agreement stipulates a $210 million cash payment upon the closing of the transaction. Finalization remains subject to customary closing conditions, including the expiration or termination of the mandatory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Financial Impact

• Receipt of $210 million in gross cash proceeds upon transaction closing
• Obligation to pay 20% of gross proceeds to the NIH under a 2018 patent license
• Net cash retention estimated at $168 million after the NIH royalty payment
• Capital influx equivalent to approximately 31% of the company's annual revenue
• Proceeds to be utilized for general corporate purposes and pipeline development

Up 3.2% since our story on 7 Oct: $14.46 when we broke it → $14.92 at the close on 13 Oct. Daily closing prices. Source: Yahoo Finance.

Show the prices

14 Sep	$13.61
15 Sep	$13.07
16 Sep	$12.88
17 Sep	$14.50
18 Sep	$14.51
21 Sep	$14.65
22 Sep	$15.62
23 Sep	$14.88
24 Sep	$14.77
25 Sep	$14.50
28 Sep	$14.41
29 Sep	$15.32
30 Sep	$15.03
1 Oct	$14.75
2 Oct	$15.22
5 Oct	$14.50
6 Oct	$14.46
7 Oct	$14.89
8 Oct	$15.29
9 Oct	$15.48
12 Oct	$15.30
13 Oct	$14.92

Business Overview

Headquartered in Novato, California, Ultragenyx is a biopharmaceutical company focused on the identification and commercialization of therapies for rare and ultra-rare genetic diseases. The company manages a diverse portfolio that includes treatments for various metabolic and musculoskeletal conditions. Beyond the recent GENGLYCOS approval, Ultragenyx is advancing several late-stage clinical programs. Notable upcoming milestones include the release of Phase 1/2 dose-finding data from the Cyprus2+ study of UX701 in Wilson disease, scheduled for the fourth quarter of 2026. The company previously reaffirmed its 2026 total revenue guidance of $730 million to $760 million.

Industry Landscape

The sale of Priority Review Vouchers has become a standard mechanism for biotechnology companies to secure non-dilutive funding. These vouchers allow a purchaser to expedite the FDA review of a future drug application, potentially reducing the review time from ten months to six. While historical prices for these assets often settled near the $100 million mark, recent market activity has demonstrated a significant premium for transferable vouchers. This divestiture follows a broader trend where rare disease specialists monetize regulatory incentives to fund capital-intensive research and development activities while focusing on their core commercial portfolios.

Ultragenyx Pharmaceutical Inc. · financial snapshot

Share price	$14.46
Market cap	$1.4B
Revenue (annual)	$673M
1-month price change	-2.63%
Sector	HealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.